{"id":221,"date":"2025-01-11T10:00:00","date_gmt":"2025-01-11T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=221"},"modified":"2025-09-07T04:14:21","modified_gmt":"2025-09-07T04:14:21","slug":"china-bd-2025-insilico-medicine-and-menarini-stemline-enters-a-570-million-usd-license-on-a-preclinical-small-molecule-asset","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/221.html","title":{"rendered":"[China BD 2025] Insilico Medicine and Menarini (Stemline) enters a 570 million USD license on a \u00a0preclinical small molecule asset"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Announced Date: 2025-01-10 (January 10, 2025)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Name: Undisclosed<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensor: InSilico Medicine (China)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensee (Buyer): Stemline Therapeutics, a subsidiary of the Menarini Group\uff08Italy\uff09<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Modality: Small &nbsp;Molecule<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Target: Undisclosed<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Potential Indication:  solid tumor cancers<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Current Stage: IND-enabling<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Scope of Authority: <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Menarini Group will be granted global rights to develop and commercialize the asset.\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Deal Detail:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Upfront payment of\u00a0 $20 million,<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Development, regulatory, and commercial  milestone payments,  total up to $550 million.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Additional royalties based on net sales in the licensed territories.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Link:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/stemline.com\/news-and-media\/menarini-group-and-insilico-medicine-enter-a-second-exclusive-global-license-agreement-for-an-ai-discovered-preclinical-asset-targeting-high-unmet-needs-in-oncology\/\">Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology &#8211; Stemline Therapeutics<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Note:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Chinese Name of Insilico Medicine\u00a0 \u82f1\u77fd\u667a\u80fd<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-01-10 (January 10, 2025) Asset Name: Undisclosed Licensor: InSilico Medicine (China) Licensee (Buyer): Stemline &hellip; <a title=\"[China BD 2025] Insilico Medicine and Menarini (Stemline) enters a 570 million USD license on a \u00a0preclinical small molecule asset\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/221.html\"><span class=\"screen-reader-text\">[China BD 2025] Insilico Medicine and Menarini (Stemline) enters a 570 million USD license on a \u00a0preclinical small molecule asset<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-221","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/221","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=221"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/221\/revisions"}],"predecessor-version":[{"id":222,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/221\/revisions\/222"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=221"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=221"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=221"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}